ClinicalTrials.gg
RecruitingNCT07499674VISUALIZE-2Updated Nov 2, 2026

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

A Phase 3 interventional study of Abenacianine and Near Infrared (NIR) Imaging in Lung Cancer and Lung Metastases, sponsored by Vergent Bioscience, Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Vergent Bioscience, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 2, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
474th of 1,908
132 · median 48
Started
2026
with 111 others
Phase 3
158 of 2,462
23 open now
Primary completion
2026-12
later than 146 of 638 live
Registered
2,397th of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 474th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 112 that started in 2026, is one of 158 in phase 3, reaches primary completion later than 146 of the 638 other live ones, and was the 2,397th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

03

Conditions studied

  • Lung Cancer
  • Lung Metastases

Browse trials for

Keywords

  • Lung Cancer
  • Metastatic Cancer in Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to sign the and comply with study procedures.
  2. Be at least 18 years of age.
  3. Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.
  4. Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.
  5. Be able to meet the following conditions:

    1. Female participants must be of non-, or,
    2. If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective from screening through Day 30 after treatment.
    3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.
  6. Have not participated in an interventional clinical trial within the last 30 days.

Exclusion criteria

Exclusion Criteria:

  1. They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.
  2. They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
  3. They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
  4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Other
    Abenacianine with surgery using Standard of Care (SOC) only

    Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC only.

    Drug: Abenacianine

  • Other
    Abenacianine with surgery using Standard of Care plus Near infrared (NIR) imaging

    Participants randomized to this arm will receive abenacianine 0.31mg/kg 12-96 hours before undergoing surgery using SOC plus NIR imaging.

    Drug: Abenacianine · Other: Near Infrared (NIR) Imaging

Interventions

  • DrugAbenacianine

    Intravenous drug to be given by syringe pump.

  • OtherNear Infrared (NIR) Imaging

    NIR imaging is a non-visible, optical technique capturing light just beyond human vision, allowing high-contrast imaging.

06

What researchers measure

Primary outcomes

  1. Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by:

    A. Intraoperative localization of one or more preoperatively identified lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation fail to identify the lesion(s). B. Identification of one or more synchronous or occult lung lesions using abenacianine with NIR imaging when standard surgical techniques using white light with or without palpation and preoperative imaging fail to identify the lesion(s).

    Time frame: Day of Surgery

Secondary outcomes

  1. Key Secondary Endpoints

    To evaluate the Population False Positive Rate for lesions (PFPR-L). A false-positive lesion is defined as tissue that fluoresces and is determined by histopathology to be normal (non-pathological).

    Time frame: Upon receipt of histopathology report (~2-3 weeks post surgery)

  2. Key Secondary

    To evaluate the Population False Positive Rate for lymph nodes (PFPR-LN). A false-positive lymph node is defined as a resected lymph node that fluoresces and is determined by histopathology to be non-cancerous.

    Time frame: Upon receipt of histopathology report. (~2-3 weeks post surgery)

  3. Key Secondary

    To evaluate the proportion of participants who have at least one lymph node resected due to fluorescence that would not have been removed under the protocol defined standard of care (SOC) and is confirmed by histopathologic examination to be cancerous.

    Time frame: Upon receipt of histopathology report. (~2-3 weeks post surgery)

  4. Other Secondary Endpoints

    To evaluate the sensitivity and specificity of abenacianine.

    Time frame: Day of surgery

Other outcomes

  1. Pharmacokinetic Endpoint

    Determine the maximum plasma concentration (Cmax) of abenacianine.

    Time frame: Pre-dose through 24 hours post-dose

  2. Pharmacokinetic Endpoint

    Determine the time to reach the maximum plasma concentration (Tmax) of abenacianine.

    Time frame: Pre-dose through 24 hours post-dase

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The joint publication will be coordinated by Vergent. There is no need for individual sites to review specific IPD from other sites.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's planned 9 months is below that.

Counting every sponsor, half of 127 studies reached it within 43 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 30, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Hoag Memorial Hospital Presbyterian is now Recruiting
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Hoag Memorial Hospital Presbyterian is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07499674
Lead sponsor
Vergent Bioscience, Inc.
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 31, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Brian York
Contact
byork@vergentbio.com
978-882-1403
Eric Bensen, PhD
Contact
ebensen@vergentbio.com
952-479-7496
Curtis Scribner, MD
study director · Vergent Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion